| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 8, 2005
From The Program in Genomics Applications: CardioGenomics Group--the Department of Genetics (H.M., S.B., C.E.S., J.G.S.), Massachusetts General Hospital (C.J.O.), and Children’s Hospital (J.N.H.), Harvard Medical School; Boston University School of Medicine, Boston (M.G.L., R.S.V., D.L., E.J.B.); the National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, Mass (M.G.L., R.S.V., C.J.O., D.L., D.C., E.J.B.); and Massachusetts Institute of Technology, Cambridge, Mass (J.N.H.). * To whom correspondence should be addressed. E-mail: seidman{at}genetics.med.harvard.edu.
Background--Mutations in sarcomere protein, PRKAG2, LAMP2, Methods and Results--We studied 1862 unrelated participants (52% women; age, 59±9 years) from the community-based Framingham Heart Study who had echocardiograms and provided DNA samples but did not have severe hypertension, aortic prosthesis, or significant aortic stenosis. Eight sarcomere protein genes, 3 storage cardiomyopathy-causing genes, and 27 mitochondrial genes were sequenced in unrelated individuals with increased LVWT (maximum LVWT >13 mm). Fifty eligible participants (9 women) had unexplained increased LVWT. We detected 8 mutations in 9 individuals (2 women); 7 mutations in 5 sarcomere protein genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL3), and 1 GLA mutation. In individuals with increased LVWT, participants with sarcomere protein and storage mutations were clinically indistinguishable from those without mutations. Conclusions--In a community-based cohort, about 3% of eligible participants had increased LVWT, of whom 18% had sarcomere protein or lipid storage gene mutations. Increased LVWT in the community is a very heterogeneous condition, which sometimes may arise from single-gene variants in one of a number of genes.
Revised on February 7, 2006
Accepted on March 31, 2006
Single-Gene Mutations and Increased Left Ventricular Wall Thickness in the Community. The Framingham Heart Study
Hiroyuki Morita MD,
-galactosidase A (GLA), and several mitochondrial genes can cause rare familial cardiomyopathies, but their contribution to increased left ventricular wall thickness (LVWT) in the community is unknown.
Related Article:
Circulation 2006 113: 2675.
This article has been cited by other articles:
![]() |
B. Oqvist, B. M. Brenner, J. P. Oliveira, A. Ortiz, R. Schaefer, E. Svarstad, C. Wanner, K. Zhang, and D. G. Warnock Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1736 - 1743. [Full Text] [PDF] |
||||
![]() |
P. Elliott and W. J. McKenna How should hypertrophic cardiomyopathy be classified?: Molecular Diagnosis for Hypertrophic Cardiomyopathy: Not Ready for Prime Time Circ Cardiovasc Genet, February 1, 2009; 2(1): 87 - 89. [Full Text] [PDF] |
||||
![]() |
P. A. Noseworthy and C. Newton-Cheh Genetic Determinants of Sudden Cardiac Death Circulation, October 28, 2008; 118(18): 1854 - 1863. [Full Text] [PDF] |
||||
![]() |
C. J. O'Donnell and E. G. Nabel Cardiovascular Genomics, Personalized Medicine, and the National Heart, Lung, and Blood Institute: Part I: The Beginning of an Era Circ Cardiovasc Genet, October 1, 2008; 1(1): 51 - 57. [Full Text] [PDF] |
||||
![]() |
L. Leatherbury, Q. Yu, B. Chatterjee, D. L. Walker, Z. Yu, X. Tian, and C. W. Lo A novel mouse model of X-linked cardiac hypertrophy Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2701 - H2711. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Morita, H. L. Rehm, A. Menesses, B. McDonough, A. E. Roberts, R. Kucherlapati, J. A. Towbin, J.G. Seidman, and C. E. Seidman Shared Genetic Causes of Cardiac Hypertrophy in Children and Adults N. Engl. J. Med., May 1, 2008; 358(18): 1899 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Arnett and for the Writing Group Summary of the American Heart Association's Scientific Statement on the Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1682 - 1686. [Full Text] [PDF] |
||||
![]() |
D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ashrafian and H. Watkins Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications: Cardiomyopathies: Therapeutics Based on Molecular Phenotype J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1251 - 1264. [Abstract] [Full Text] [PDF] |
||||
![]() |
Minerva BMJ, June 17, 2006; 332(7555): 1460 - 1460. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |